Korea Exchange · Healthcare
Jeil Pharma stock from India: price, numbers and tax
Jeil Pharma (002620) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Jeil Pharma at a glance
- Price
- ₩7,550.00-₩10.00 (0.13%)
- Market cap
- ₩115.90B
- Day range
- ₩7,480.00 – ₩7,600.00
- P/E
- 13.73
- Dividend yield
- 0.93%
- Volume
- 2.96K
- 1 month
- -0.79%
- 6 months
- -7.36%
- YTD
- -6.09%
- 1 year
- -16.48%
- 5 years
- -57.22%
Jeil Pharma statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩657.6B | ₩779.8B | ₩804.0B | ₩793.0B | ₩762.6B |
| Gross profit | ₩226.3B | ₩206.5B | ₩214.6B | ₩180.5B | ₩180.5B |
| Operating income | ₩15.1B | −₩11.6B | ₩20.9B | −₩7.5B | ₩1.6B |
| Net income | ₩14.6B | −₩51.2B | −₩16.2B | −₩83.1B | −₩12.9B |
| Earnings per share | ₩953.37 | −₩3,323.31 | −₩1,059.00 | −₩5,416.22 | −₩838.38 |
| EBITDA | ₩30.0B | −₩38.7B | ₩9.2B | −₩67.0B | ₩6.1B |
| Total assets | ₩876.0B | ₩890.4B | ₩880.0B | ₩865.7B | ₩892.4B |
| Total debt | ₩167.4B | ₩155.2B | ₩214.1B | ₩162.6B | ₩115.1B |
| Cash and short-term investments | ₩79.3B | ₩75.9B | ₩59.1B | ₩53.4B | ₩47.2B |
| Shareholders' equity | ₩318.7B | ₩306.9B | ₩319.5B | ₩337.8B | ₩411.7B |
| Operating cash flow | ₩390.3M | ₩4.5B | −₩4.4B | −₩20.8B | ₩13.4B |
| Free cash flow | −₩7.9B | −₩2.3B | −₩14.3B | −₩42.2B | −₩10.3B |
| Capital expenditure | −₩8.3B | −₩6.9B | −₩9.8B | −₩21.4B | −₩23.7B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Whan In Pharm | 016580.KS | ₩10,180.00 | ₩188.17B |
| Hyundai Pharmaceutical | 004310.KS | ₩7,760.00 | ₩181.97B |
| Ilsung Is | 003120.KS | ₩22,350.00 | ₩160.07B |
| Jeil Pharmaceutical | 271980.KS | ₩10,050.00 | ₩147.78B |
| Kyongbo Pharmaceutical | 214390.KS | ₩5,500.00 | ₩131.49B |
| SAMSUNG PHARM. | 001360.KS | ₩1,376.00 | ₩129.51B |
| HANDOK | 002390.KS | ₩8,600.00 | ₩111.72B |
| CKD Bio | 063160.KS | ₩14,010.00 | ₩76.86B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Jeil Pharma from India
What Jeil Pharma does
Jeil Pharma Holdings Inc. is a South Korean pharmaceutical enterprise focused on the production and sale of active pharmaceutical ingredients (APIs), incrementally modified drugs (IMDs), and generic pharmaceuticals. The company's comprehensive API portfolio encompasses a variety of therapeutic areas, including antimicrobials, gastrointestinal remedies, cardiovascular medications, neuropsychiatric treatments, oncology drugs, endocrinology products, urology solutions, antivirals, and antihistamines, in addition to transdermal patch formulations. Jeil Pharma operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Jeil Pharma shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.